Pfizer/IVGTT/Ziprasidone/Olanzapine
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00205725 |
Recruitment Status
:
Completed
First Posted
: September 20, 2005
Last Update Posted
: March 13, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia Type 2 Diabetes Mellitus | Drug: Ziprasidone, Olanzapine | Not Applicable |
This proposal aims to use a well-characterized procedure, the modified Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT), to characterize the glucoregulatory effects of the two most commonly prescribed atypical antipsychotic medications, ziprasidone and olanzapine, in comparison to the conventional antipsychotic haloperidol. Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions. While abnormalities in glucose regulation were first reported in schizophrenia prior to the introduction of antipsychotic medications, antipsychotic treatment may contribute significantly to abnormalities in glucose regulation.
Recently, the adverse effect of antipsychotic medications on systemic glucose regulation has received increased attention as investigators noted prominent adverse glucoregulatory effects associated with certain newer antipsychotic medications. Abnormal glucose regulation and new-onset type 2 diabetes have been reported during clozapine and olanzapine treatment. Complicating the study of antipsychotic-induced changes in glucose regulation, increased adiposity can decrease insulin sensitivity, and antipsychotics can increase adiposity and body mass index (BMI). However, abnormal glucose regulation and type 2 diabetes can occur during clozapine treatment in the absence of weight gain, suggesting that changes in glucose regulation can occur independent of drug-induced increases in BMI. Consistent with this, our preliminary studies indicate that important effects of clozapine and olanzapine on glucose regulation are not accounted for by differences in BMI. This proposal will compare the effects of olanzapine, ziprasidone and haloperidol on well-defined measures of glucose regulation.
This proposal specifically hypothesizes that olanzapine treatment will be associated with decreases in insulin sensitivity (SI), without effects on insulin secretion. Treatment-related effects on glucose effectiveness (SG) will be explored.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 120 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Glucose Regulation During Ziprasidone Treatment |
Study Start Date : | November 2000 |
Actual Primary Completion Date : | October 2006 |
Actual Study Completion Date : | October 2006 |

- Effects of olanzapine/ziprasidone/haloperidol on glucose regulation
- Explore treatment-related effects on glucose effectiveness

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients: meets DSM-IV criteria for schizophrenia, any type, or schizoaffective disorder;
- aged 18 to 60 years;
- able to give informed consent;
- no medication changes for 2 weeks prior to and during the period of study;
- Patients: currently taking an antipsychotic.
Exclusion Criteria:
- Controls: Axis I psychiatric disorder criteria met except for substance use disorders as below;
- meets DSM-IV criteria for the diagnoses of substance abuse or dependence within the past six months;
- involuntary legal status (as per Missouri law);
- the presence of any serious medical disorder that may (as confirmed by peer-reviewed literature) confound the assessment of symptoms, relevant biologic measures or diagnosis;
-
the following conditions are currently identified:
- insulin- or non-insulin-dependent diabetes mellitus;
- any intra-abdominal or intrathoracic surgery or limb amputation within the prior 6 months;
- any diagnosed cardiac condition causing documented hemodynamic compromise;
- any diagnosed respiratory condition causing documented or clinically recognized hypoxia;
- pregnancy or high dose estrogens, fever, narcotic therapy, acute sedative hypnotic withdrawal, corticosteroid or spironolactone therapy, dehydration, epilepsy, endocrine disease, high-dose benzodiazepine therapy (> 25 mg/day of diazepam), or any medical condition known to interfere with glucose utilization;
- meets DSM-IV criteria for Mental Retardation (mild or worse).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00205725
United States, Missouri | |
Washington University School of Medicine, Psychiatry Dept. | |
St. Louis, Missouri, United States, 63110 |
Principal Investigator: | John W. Newcomer, M.D. | Washington University School of Medicine and Florida Atlantic University |
Publications of Results:
Responsible Party: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00205725 History of Changes |
Other Study ID Numbers: |
Pfizer IVGTT/941273 |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | March 13, 2014 |
Last Verified: | March 2014 |
Keywords provided by Washington University School of Medicine:
Schizophrenia BMI T2DM |
Additional relevant MeSH terms:
Diabetes Mellitus Schizophrenia Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Olanzapine Ziprasidone Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Gastrointestinal Agents Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Serotonin Antagonists Dopamine Antagonists Dopamine Agents |